Key Performance
More- Earnings Score: 54
- Momentum Score: 27
- True Yield: 87
- Financial Health Score: 1
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Class action lawsuits have been filed against AeroVironment, Calix, Zoetis, and Lucid Group, alleging that company executives made materially false statements and failed to disclose material adverse facts about their businesses. The lawsuits cover various issues including understated competition, supply chain problems, declining product adoption, and manufacturing disruptions. Lead plaintiff deadlines range from July 27-28, 2026.
07/27/2026, 10:49 AM • GlobeNewswire
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales in dermatology products Apoquel and Cytopoint. Investors who purchased securities during this period may be eligible for compensation.
07/22/2026, 11:10 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts during the period from January 14, 2025 to May 6, 2026. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply to be appointed as lead plaintiff.
07/20/2026, 5:50 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and declining sales of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. The deadline to file a lead plaintiff motion is July 27, 2026.
07/20/2026, 1:53 PM • GlobeNewswire
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period from January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities during this period may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.
07/19/2026, 7:47 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the class period of January 14, 2025 through May 6, 2026. The lawsuit alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. Zoetis's stock fell 21.5% on May 7, 2026, following disappointing first quarter results showing significant decline in its Companion Animal business. Investors have until July 27, 2026, to file for lead plaintiff status.
07/18/2026, 9:40 AM • GlobeNewswire
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period of January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its flagship products Librela, Simparica Trio, and dermatology treatments Apoquel and Cytopoint due to safety concerns, competition, and market share losses. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 lead plaintiff deadline.
07/16/2026, 2:12 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making materially false statements about product growth and market positioning. The complaint claims the company failed to disclose weakening adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales of dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are encouraged to join the case.
07/16/2026, 12:00 PM • GlobeNewswire
Zoetis Inc. faces a securities class action lawsuit covering January 14, 2025 through May 6, 2026, with CEO Kristin Peck and CFO Wetteny Joseph named as individual defendants. The lawsuit alleges they certified misleading statements about companion animal product performance while safety concerns and competitive losses mounted. Zoetis shares fell 21.5% to $87.31 on May 7, 2026 following corrective disclosures. The lead plaintiff deadline is set for July 27, 2026.
07/14/2026, 10:54 AM • GlobeNewswire
The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.
07/13/2026, 7:32 AM • GlobeNewswire
Rosen Law Firm is notifying Zoetis Inc. investors who purchased securities between January 14, 2025 and May 6, 2026 of an important July 27, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of flagship products Librela and Simparica Trio, as well as market share losses in dermatology products due to FDA safety warnings and increased competition.
07/10/2026, 5:49 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false and misleading statements regarding its business operations between January 14, 2025 and May 6, 2026. The complaint alleges the company failed to disclose weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply as lead plaintiff.
07/10/2026, 12:51 PM • GlobeNewswire
Glancy Prongay Wolke & Rotter LLP announced a securities fraud class action lawsuit against Zoetis Inc., alleging the company made materially false statements and failed to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and reduced growth outlooks. The deadline to file a lead plaintiff motion is July 27, 2026.
07/06/2026, 1:48 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making materially false and misleading statements about its Companion Animal segment products. The complaint claims the company failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses for Simparica Trio to lower-priced competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are eligible to join the class action.
07/06/2026, 12:00 PM • GlobeNewswire
ZTS 截止日期提醒：全球頂級律師事務所 ROSEN 建議損失超過 10 萬美元的 Zoetis Inc. 投資者趕及對 ZTS 提出證券集體訴訟的重要截止日期前聘請律師
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025 and May 6, 2026. The lawsuit alleges that Zoetis made false and misleading statements about market share growth and product adoption while failing to disclose significant market share losses in key products including Librela, Simparica Trio, Apoquel, and Cytopoint due to increased competition and FDA safety warnings. The deadline to apply as lead plaintiff is July 27, 2026.
07/04/2026, 6:15 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 07/31/2026
Company Profile
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.